Revenue

EBITDA

Earnings

Price per share at the end of the period divided by the last reported earnings

Free Cash Flow

Core Molding Technologies, Inc., together with its subsidiaries, operates as a molder of thermoplastic and thermoset structural products. The company offers a range of manufacturing processes that include compression molding of sheet molding compound, resin transfer molding, liquid molding of dicyclopentadiene, spray-up and hand-lay-up, direct long-fiber thermoplastics, and structural foam and structural web injection molding. It serves various markets, including medium and heavy-duty truck, automobile, power sport, construction, agriculture, building products, and other commercial markets in the United States, Mexico, Canada, and internationally. The company was formerly known as Core Materials Corporation and changed its name to Core Molding Technologies, Inc. in August 2002. Core Molding Technologies, Inc. was incorporated in 1996 and is headquartered in Columbus, Ohio.

Core Molding Technologies, Inc.

The significance of a company's longevity in the market

Years since IPO

Evaluation of recent trends and improvements in the company's revenue

Revenue Growth

Assessment of recent increases in earnings per share, indicating profitability

EPS Growth

Review of the company's ability to generate free cash flow over recent periods

FCF Growth

Analysis of Return on Equity, showing how effectively the company uses equity to generate profits

Examination of debt levels using Debt/Assets and Debt/EBITDA to ensure manageable leverage

Debt

COLUMBUS, OHIO, NOV. 05, 2025 (GLOBE NEWSWIRE) -- CORE MOLDING TECHNOLOGIES, INC. (NYSE AMERICAN: CMT) (CORE MOLDING, CORE OR THE COMPANY), A LEADING ENGINEERED MATERIALS COMPANY SPECIALIZING IN MOLDED STRUCTURAL PRODUCTS, PRINCIPALLY IN BUILDING PRODUCTS, INDUSTRIAL AND UTILITIES, MEDIUM AND HEAVY-DUTY TRUCK AND POWERSPORTS INDUSTRIES ACROSS THE UNITED STATES, CANADA AND MEXICO TODAY ANNOUNCED THAT MANAGEMENT WILL PARTICIPATE IN THE 17TH ANNUAL SOUTHWEST IDEAS INVESTOR CONFERENCE AT THE WESTIN IRVING CONVENTION CENTER LAS COLINAS ON NOVEMBER 19, 2025.

CORE MOLDING TECHNOLOGIES TO PRESENT AND HOST 1X1 MEETINGS AT THE 17TH ANNUAL SOUTHWEST IDEAS INVESTOR CONFERENCE ON NOVEMBER 19, 2025

TORONTO, ONTARIO--(NEWSFILE CORP. - LE 4 NOVEMBRE/NOVEMBER 2025) - EFFECTIVE IMMEDIATELY, THE FOLLOWING COMPANIES

CSE BULLETIN: SUSPENSIONS - CMT, GAND, SASY

- CMT-SORD PROGRAM ADVANCES; MEETING SCHEDULED WITH THE FDA IN Q3 2025 TO DISCUSS GOVORESTAT FOR THE TREATMENT OF CMT-SORD

APPLIED THERAPEUTICS REPORTS SECOND QUARTER 2025 FINANCIAL RESULTS

COLUMBUS, OHIO, AUG. 12, 2025 (GLOBE NEWSWIRE) -- CORE MOLDING TECHNOLOGIES, INC. (NYSE AMERICAN: CMT) (CORE MOLDING, CORE OR THE COMPANY), A LEADING ENGINEERED MATERIALS COMPANY SPECIALIZING IN MOLDED STRUCTURAL PRODUCTS, PRINCIPALLY IN BUILDING PRODUCTS, INDUSTRIAL AND UTILITIES, MEDIUM AND HEAVY-DUTY TRUCK AND POWERSPORTS INDUSTRIES ACROSS THE UNITED STATES, CANADA AND MEXICO TODAY ANNOUNCED THAT MANAGEMENT WILL PARTICIPATE IN THE 16TH ANNUAL MIDWEST IDEAS INVESTOR CONFERENCE AT THE INTERCONTINENTAL CHICAGO MAGNIFICENT MILE IN CHICAGO ON AUGUST 26, 2025.

CORE MOLDING TECHNOLOGIES TO PRESENT AND HOST 1X1 MEETINGS AT THE 16TH ANNUAL MIDWEST IDEAS INVESTOR CONFERENCE ON AUGUST 26, 2025

CEO DAVE DUVALL TO RETIRE MAY 2026, COO ERIC PALOMAKI TO SUCCEED DUVALL CEO DAVE DUVALL TO RETIRE MAY 2026, COO ERIC PALOMAKI TO SUCCEED DUVALL

CORE MOLDING TECHNOLOGIES ANNOUNCES 2026 LEADERSHIP TRANSITION

COLUMBUS, OHIO, JULY 17, 2025 (GLOBE NEWSWIRE) -- CORE MOLDING TECHNOLOGIES, INC. (NYSE AMERICAN: CMT) (CORE MOLDING, CORE OR THE COMPANY), A LEADING ENGINEERED MATERIALS COMPANY SPECIALIZING IN MOLDED STRUCTURAL PRODUCTS, PRINCIPALLY IN BUILDING PRODUCTS, UTILITIES, TRANSPORTATION AND POWERSPORTS INDUSTRIES ACROSS NORTH AMERICA, TODAY ANNOUNCES THAT IT WILL RELEASE ITS SECOND QUARTER FISCAL 2025 RESULTS ON TUESDAY, AUGUST 5, 2025, BEFORE THE MARKET OPENS. IN CONJUNCTION WITH THE RELEASE, THE COMPANY HAS SCHEDULED A CONFERENCE CALL, WHICH WILL BE BROADCAST LIVE OVER THE INTERNET THE SAME DAY AT 10:00AM EASTERN.

CORE MOLDING TECHNOLOGIES ANNOUNCES TIMING OFSECOND QUARTER FISCAL 2025 RESULTS

WASHINGTON , JUNE 10, 2025 /PRNEWSWIRE/ --VANDA PHARMACEUTICALS INC. (VANDA) (NASDAQ:VNDA) TODAY ANNOUNCED THE FIRST DOSE IN THEFIRST-IN-HUMANCLINICAL TRIAL TO EVALUATE THE SAFETY AND TOLERABILITY OF VCA-894A, AN ANTISENSE OLIGONUCLEOTIDE (ASO) THERAPEUTIC, FOR A PATIENT WITH A RARE VARIANT IN THEIGHMBP2GENE CAUSING CHARCOT-MARIE-TOOTH DISEASE TYPE 2S (CMT2S). VCA-894A IS BEING DEVELOPED FOR A PATIENT WHO WAS FIRST DIAGNOSED AT THE AGE OF 5 WITH A RARE SUBTYPE OF CMT DISEASE KNOWN AS CMT2S.1CMT2S IS AN INHERITED NEUROMUSCULAR DISORDER THAT PROGRESSIVELY LEADS TO MUSCLE WEAKNESS AND LOSS OF MOTOR FUNCTION, AND HAS AN ESTIMATED PREVALENCE OF LESS THAN 1 IN 1,000,000 WORLDWIDE.2THE SEVERITY AND CLINICAL PRESENTATIONS OF CMT2S ARE INFLUENCED BY THE DIVERSE GENETIC VARIANTS ASSOCIATED WITH CMT DISEASE.

VANDA PHARMACEUTICALS ANNOUNCES FIRST PATIENT DOSED IN A TRIAL EVALUATING VCA-894A IN CHARCOT-MARIE-TOOTH DISEASE TYPE 2S

COLUMBUS, OHIO, JUNE 05, 2025 (GLOBE NEWSWIRE) -- CORE MOLDING TECHNOLOGIES, INC. (NYSE AMERICAN: CMT) (CORE MOLDING, CORE OR THE COMPANY), A LEADING ENGINEERED MATERIALS COMPANY SPECIALIZING IN MOLDED STRUCTURAL PRODUCTS, PRINCIPALLY IN BUILDING PRODUCTS, INDUSTRIAL AND UTILITIES, MEDIUM AND HEAVY-DUTY TRUCK AND POWERSPORTS INDUSTRIES ACROSS THE UNITED STATES, CANADA AND MEXICO TODAY ANNOUNCED THAT MANAGEMENT WILL PARTICIPATE IN THE 15TH ANNUAL EAST COAST IDEAS INVESTOR CONFERENCE AT THE WESTIN TIME SQUARE IN NEW YORK CITY ON JUNE 11, 2025.

CORE MOLDING TECHNOLOGIES TO PRESENT AND HOST 1X1 MEETINGS AT THE15TH ANNUAL EAST COAST IDEAS INVESTOR CONFERENCE ON JUNE 11, 2025

COLUMBUS, OHIO, MAY 22, 2025 (GLOBE NEWSWIRE) -- CORE MOLDING TECHNOLOGIES, INC. (NYSE AMERICAN: CMT) (CORE MOLDING, CORE OR THE COMPANY), A LEADING ENGINEERED MATERIALS COMPANY SPECIALIZING IN MOLDED STRUCTURAL PRODUCTS, PRINCIPALLY IN BUILDING PRODUCTS, INDUSTRIAL AND UTILITIES, MEDIUM AND HEAVY-DUTY TRUCK AND POWERSPORTS INDUSTRIES ACROSS THE UNITED STATES, CANADA AND MEXICO TODAY ANNOUNCED THE RELEASE OF ITS THIRD ANNUAL SUSTAINABILITY REPORT, WHICH HIGHLIGHTS THE COMPANY'S ONGOING COMMITMENT TO RESPONSIBLE BUSINESS PRACTICES, COMMUNITY ENGAGEMENT, AND ENVIRONMENTAL STEWARDSHIP.

CORE MOLDING TECHNOLOGIES PUBLISHES ITS 3RD ANNUAL SUSTAINABILITY REPORT

SLOWING OF PROGRESSION OF DISEASE OBSERVED VIA MRI AT 24 MONTHS IMPROVEMENTS IN OUTCOMES AND REDUCTION IN SORBITOL MAINTAINED THROUGH 24 MONTHS STATISTICALLY SIGNIFICANT CORRELATION BETWEEN ABSOLUTE REDUCTION IN SORBITOL AND CHANGE IN 10MWRT AND CMT-FOM LOWER LIMB DOMAIN AT 12 MONTHS, THOUGH THE PRIMARY ENDPOINT OF 10MWRT AT 12 MONTHS WAS NOT STATISTICALLY SIGNIFICANT (THE MEASURE HAS SINCE BEEN REMOVED FROM THE CMT-FOM CLINICAL OUTCOMES ASSESSMENT BASED UPON THE RESULTS OF THE ACT-CMT STUDY*) STATISTICALLY SIGNIFICANT IMPROVEMENT IN CMT-HI AND STATISTICALLY SIGNIFICANT CORRELATION BETWEEN PERCENT CHANGE IN SORBITOL AND CHANGE IN CMT-HI AT 12 MONTHS TREATMENT WITH GOVORESTAT IN CMT-SORD-NULL RATS DEMONSTRATED A HIGHLY STATISTICALLY SIGNIFICANT 37% (P=0.005) REDUCTION OF SORBITOL IN THE SCIATIC NERVE, THE TISSUE OF INTEREST, AFTER TREATMENT WITH GOVORESTAT.REFLECTIVE OF THEPERIPHERAL NEUROPATHY EXPERIENCED BY PATIENTS WITH CMT-SORD. GOVORESTAT REMAINS GENERALLY SAFE AND WELL TOLERATED COMPANY REMAINS COMMITTED TO POTENTIAL NDA SUBMISSION OF GOVORESTAT FOR TREATMENT OF CMT-SORD IN 2025 NEW YORK, MAY 18, 2025 (GLOBE NEWSWIRE) -- APPLIED THERAPEUTICS, INC. (NASDAQ: APLT), A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY DEDICATED TO CREATING TRANSFORMATIVE TREATMENTS FOR RARE DISEASE, TODAY PRESENTED FULL 12-MONTH CLINICAL RESULTS AND NEW TOPLINE DATA FROM 18 AND 24 MONTHS FROM THE INSPIRE PHASE 2/3 TRIAL OF GOVORESTAT (AT-007) FOR THE TREATMENT OF SORBITOL DEHYDROGENASE (SORD) DEFICIENCY, A SUBTYPE OF CHARCOT-MARIE-TOOTH (CMT) DISEASE, IN AN ORAL PRESENTATION AT THE PERIPHERAL NERVE SOCIETY (PNS) 2025 ANNUAL MEETING, BEING HELD MAY 17-20, 2025 IN EDINBURGH, SCOTLAND.

APPLIED THERAPEUTICS PRESENTS FULL 12-MONTH CLINICAL RESULTS AND NEW TOPLINE DATA FROM INSPIRE PHASE 2/3 TRIAL OF GOVORESTAT IN CMT-SORD IN LATE-BREAKING ORAL PRESENTATION AT THE PERIPHERAL NERVE SOCIETY 2025 ANNUAL MEETING

Core Molding Technologies, Inc.

CMT

Price

Financials Overview

Financial Reports

No items found.

Press Releases

Core Molding Technologies, Inc.

CMT.css-1jgtvd5{-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;width:1em;height:1em;overflow:hidden;display:inline-block;text-align:center;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;font-size:1.5rem;}

Price

Financials Overview

Financial Reports

No items found.

Press Releases

CMT